<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000044908"><TermName>suberoylanilide hydroxamic acid</TermName><TermPronunciation>(SOO-beh-royl-AN-ih-lide hy-drok-SA-mik A-sid)</TermPronunciation><TermDefinition><DefinitionText>A drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Suberoylanilide hydroxamic acid is a type of histone deacetylase inhibitor. Also called SAHA, vorinostat,  and Zolinza.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000706122" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;suberoylanilide hydroxamic acid&quot;" language="en" id="_3"/><MediaLink ref="CDR0000706121" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;ácido hidroxámico suberoilanilida&quot;" language="es" id="_4"/><SpanishTermName>ácido hidroxámico suberoilanilida</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar el linfoma cutáneo de células T que no mejora, empeora o vuelve durante el tratamiento con otros medicamentos o después de este. También está en estudio para el tratamiento de otros tipos de cáncer. El ácido hidroxámico suberoilanilida es un tipo de inhibidor de la histona desacetilasa. También se llama AHSA, vorinostat,  y Zolinza.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateLastModified>2008-11-14</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000513752">Vorinostat</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
